Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies

Abstract

Molecular profiling of CTC may offer superior prognostic information with regard to risk assessment for recurrence and predictive judgement of therapeutical regimens.

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

“…In another study, 13% of 431 early BC patients were CTC-positive according to the AdnaTest®; however, no correlation with clinical outcome was reported [65]. In metastatic BC, CTC detection by AdnaTest® was reported in 52% of 42 women and predicted therapy response in 78% of cases [66]. Finally using immunomagnetic tumor cell enrichment and a multi-marker quantitative PCR based assay, CTCs were detected in 7.9% of 733 stage I/II breast cancer patients with a median follow-up time of 7.6 years and their detection was an independent predictor of metastasis-free survival and breast cancer specifi c survival [67].…”

Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review)

“…This expression is limited to the adult mammary gland (120) and related to mammary gland proliferation and differentiation (110,(121)(122)(123)(124)(125), but is commonly absent in healthy breast tissue samples. The detection frequencies seem to vary (126)(127)(128), sensitivity of qPCR for detection of hMAM mRNA shows a broad range even in metastatic breast cancer (128)(129)(130), imposing doubt on the utility of this marker (118), but a combination of hMAM with survivin and hTERT increases the sensitivity of CTC detection (131), pointing towards the use of multimarker PCR (132). Furthermore, no correlation could be found between the expression of hMAM and nodal state, tumour size and grading (109,121,132).…”

Novel Tissue Types for the Development of Genomic Biomarkers

“…Recently, CTCs have been the target of multiple molecular profiling studies (Bosma et al, 2002;Punnoose et al, 2010;Smirnov et al, 2005;Tewes et al, 2009). mRNA expression and DNA mutations can be measured from captured CTCs.…”

“…mRNA expression and DNA mutations can be measured from captured CTCs. RT-PCR using a multi-marker panel of cancer-associated genes was found to be the most sensitive technique for the detection of CTC in blood of breast cancer patients (Bosma et al, 2002;Tewes et al, 2009). Another approach involves the analysis of CTC-enriched samples by microarray gene expression profiling, where numerous genes like S100A14 and S100A16 have been detected (Smirnov et al, 2005).…”